Once daily dosing improves adherence to antiretroviral therapy

AIDS and Behavior

Volumn 15, Issue 7, 2011, Pages 1397-1409

  Raboud, Janet ^a,b   Li, Maggie ^a   Walmsley, Sharon ^a,b   Cooper, Curtis ^c   Blitz, Sandra ^a   Bayoumi, Ahmed M ^d   Rourke, Sean ^b,d,e   Rueda, Sergio ^d,e   Rachlis, Anita ^f   Mittmann, Nicole ^f   Smieja, Marek ^g   Collins, Evan ^a,b   Loutfy, Mona R ^h,i  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e ONTARIO HIV TREATMENT NETWORK   (Canada)

^f SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^g MCMASTER UNIVERSITY   (Canada)

^h MAPLE LEAF MEDICAL CLINIC   (Canada)

ⁱ WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

Adherence; Antiretroviral therapy; HIV; Once daily dosing

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; CANADA; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DRUG ADMINISTRATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PSYCHOLOGICAL ASPECT; SOCIOECONOMICS; STATISTICS; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; ONTARIO; PATIENT COMPLIANCE; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84855180344     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-010-9818-5     Document Type: Article

References (44)

1. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21-30. (Pubitemid 30432540)
2. Gross R, Yip B, Lo Re V III, et al. A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis. 2006;194:1108-14. (Pubitemid 44547650)
3. Tam LW, Chui CK, Brumme CJ, et al. The relationship between resistance and adherence in drug-naive individuals initiating HAART is specific to individual drug classes. JAIDS. 2008;49(3): 266-71.
4. Lima VD, Harrigan R, Murray M, et al. Differential impact of adherence on long-term treatment response among naïve HIVinfected individuals. AIDS. 2008;22:2371-80.
5. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43:939-41. (Pubitemid 44435526)
6. Shuter J. Forgiveness of non-adherence to HIV-1 antiretroviral therapy. J Antimicrobial Chemother. 2008;61(4):769-73. (Pubitemid 351426058)
7. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009; 1-161. Available at http://www.aids info.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 1 Apr 2010.
8. Plankey M, Bacchetti P, Jin C, et al. Self perception of body fat changes and HAART adherence in the women's interagency HIV study. AIDS Behav. 2009;13(1):53-9.
9. Turner RJ, Wheaton B, Lloyd DA. The epidemiology of social stress. Am Sociol Rev. 1995;60(1):104-25.
10. Hinkin CH, Hardy DJ, Mason KI, et al. Medication adherence in HIV-infected adults: Effect of patient age, cognitive status, and substance abuse. AIDS. 2004;18(Suppl 1):S19-25. (Pubitemid 38365902)
11. Malta M, Magnanini MM, Strathdee S, Bastos FI. Adherence to Antiretroviral Therapy among HIV infected Drug users: A Meta Analysis. AIDS Behav. 2010;14(4):731-47.
12. Cardarelli R, Weis S, Adams E, et al. General health status and adherence to antiretroviral therapy. J Int Assoc Physicians AIDS Care. 2008;7:123-9.
13. Merenstein DJ, Schneider MF, Cox C, et al. Association between living with children and adherence to highly active antiretroviral therapy in the Women's Interagency HIV Study. Pediatrics. 2008; 121(4):e787-93.
14. Boer-van De, der Kolk M, Sprangers MAG, van der Ende M, Schreij G, de Wolf F, Nieuwkerk PT. Lower perceived necessity of HAART predicts lower treatment adherence and worse virological response in the ATHENA cohort. JAIDS. 2008;49:460-1.
15. Gonzalez JS, Penedo FJ, Llabre MM, et al. Physical symptoms, beliefs about medications, negative mood, long-term HIV medication adherence. Ann Behav Med. 2007;34(1):46-55. (Pubitemid 47481224)
16. Moody KA, Ebrahim D, Deschamps AED, De Geest S, Spirig R. The Relationship of Symptom Experience and Nonadherence in HIV. 3rd International Conference on HIV Treatment Adherence, March 17-18, 2008 Jersey City, NJ.
17. Applebaum AJ, Richardson MA, Brady SM, Brief DJ, Keane TM. Gender and other psychosocial factors as predictors of adherence to highly active antiretroviral therapy (HAART) in adults with comorbid HIV/AIDS, psychiatric and substancerelated disorder. AIDS Behav. 2009;13(1):60-5.
18. Leserman J, Ironson G, O'Cleirigh C, Fordiani JM, Balbin E. Stressful life events and adherence in HIV. AIDS Patient Care STDs. 2008;22(5):403-11. (Pubitemid 351733239)
19. Ammassari A, Antinori A, Aloisi MS, et al. Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics. 2004;45:394-402. (Pubitemid 39166911)
20. Gordillo V, del Amo J, Soriano V, et al. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS. 1999;13:1763-9. (Pubitemid 30015725)
21. Cruess DG, Petitto JM, Leserman J, et al. Depression and HIV infection: Impact on immune function and disease progression. CNS Spectrosc. 2003;8:52-8. (Pubitemid 36760176)
22. Mugavero M, Ostermann J, Whetten K, et al. Barriers to antiretroviral adherence: The importance of depression, abuse, and other traumatic events. AIDS Patient Care STDS. 2006;20:418-28. (Pubitemid 43993096)
23. Tucker JS, Burnam MA, Sherbourne CD, et al. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med. 2003;114:573-80. (Pubitemid 36577260)
24. Bogart LM, Wagner G, Galvan FH, Banks D. Conspiracy beliefs about HIV are related to antiretroviral treatment nonadherence among african american men with HIV. J Acquir Immune Defic Syndr. 2010;53(5):648-55.
25. Sayles JN, Wong MD, Kinsler JJ, Martins D, Cunningham WE. The association of stigma with self-reported access to medical care and antiretroviral therapy adherence in persons living with HIV/AIDS. J Gen Intern Med. 2009;24(10):1101-8.
26. Pope H, White D, Cherry C, et al. The association between health literacy and HIV treatment adherence: Further evidence from objectively measured medication adherence. J Int Assoc Physicians AIDS Care. 2008;7:317.
27. Brion JM, Menke EM, et al. Perspectives regarding adherence to prescribed treatment in highly adherent HIV-infected gay men. J Assoc Nurses AIDS Care. 2008;19(3):181-91.
28. Horberg MA, Tang B, Towner WJ, et al. Two versus three pills daily HAART-does it make a difference? 3rd International conference on HIV treatment adherence, March 17-18, 2008 Jersey City, NJ.
29. Martin M, Del Cacho E, Codina C, et al. Relationship between adherence level, type of antiretroviral regimen, and plasma HIV Type 1 RNA viral load: A prospective cohort study. AIDS Res Hum Retroviruses. 2008;24:1263-8.
30. Boyle BA, Jayaweera D, Witt MD, Grimm K, Maa JF, Seekins DW. Randomization to a once-daily stavudine extended release/ lamivudine/efavirenz versus a more frequent regimen improves adherence while maintaining virologic suppression. HIV Clin Trials. 2008;9:164-76. (Pubitemid 351892870)
31. Molina JM, Podsadecki TJ, Johnson MA, et al. A lopinavir/ ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks. AIDS Res Hum Retroviruses. 2007;23:1505-14.
32. Jayaweera D, Dejesus E, Nguyen KL, Grimm K, Butcher D, Seekins DW. Virologic suppression, treatment adherence, and improved quality of life on a once-daily efavirenz-based regimen in treatment-Naïve HIV-1-infected patients over 96 weeks. HIV Clin Trials. 2009;10(6):375-84.
33. Cooper V, Horne R, Gellaitry G, et al. The impact of once-nightly versus twice-daily dosing and baseline beliefs about HAART on adherence to efavirenz-based haart over 48 weeks: The NOCTE study. JAIDS. 2010;53(3):369-77.
34. Maitland D, Jackson A, Osorio J, Mandalia S, Gazzard BG, Moyle GJ, Epivir-Ziagen (EZ) Switch Study Team. Switching from twicedaily abacavir and lamivudine to the once daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy. HIV Med. 2008;9:667-92.
35. Parienti JJ, Massari V, Reliquet V, et al. Effect of twice-daily nevirapine on adherence in HIV-1 infected patients: A randomized controlled study. AIDS. 2007;21:2217-22. (Pubitemid 350287220)
36. Eron JJ, Feinberg J, Kessler HA, et al. Once-daily versus twicedaily lopinavir/ritonavir in antiretroviral-naïve HIV positive patients: A 48-week randomized clinical trial. J Infect Dis. 2004;189:265-72. (Pubitemid 38147251)
37. Bangsberg DR, Ragland K, Monk A, Deeks SG. A one-pill, oncedaily, fixed-dose combination (FDC) of efavirenz, emtricitabine and tenofovir disoproxil fumarate (EFV/FTC/TDF) regimen is associated with higher unannounced pill count adherence than non-one pill, once daily. Conference on Retroviruses and Opportunistic Infections, San Francisco 2010.
38. Justice AC, Holmes W, Gifford AL, et al. Development and validation of a self-completed HIV symptom index. J Clin Epidemiol. 2001;54(12):S77-90. (Pubitemid 34013693)
39. Sherbourne CD, Stewart AL. The MOS social support survey. Soc Sci Med. 1991;32(6):705-14.
40. Radloff LS. The CES-D scale: A self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1(3):385-401.
41. Carver CS. You want to measure coping but your protocol's too long: Consider the brief COPE. Int J Behav Med. 1997;4(1):92-100. (Pubitemid 127532310)
42. Carver CS, Scheier MF, Weintraub KJ. Assessing coping strategies: A theoretically based approach. J Pers Soc Psychol. 1989;56(2):267-83.
43. Pearlin LI, Schooler C. The structure of coping. J Health Soc Behav. 1978;19(1):2-21. (Pubitemid 8303939)
44. Berger BE, Ferrans CE, Lashley FR. Measuring stigma in people with HIV: Psychometric assessment of the HIV stigma scale. Res Nurs Health. 2001;24(6):518-29. (Pubitemid 33604361)